

# Oversight of Genetic Testing

Gail Javitt  
Genetics and Public Policy Center  
Johns Hopkins University



Search

Newsletter Signup

Text Size: AAA

ABOUT THE CENTER

NEWS & EVENTS

SCIENCE

POLICY & PUBLIC OPINION

PUBLICATIONS & RESOURCES

NEWS

XML

05/28/08 Statement of Director Kathy Hudson regarding announced resignation of NHGRI's Francis Collins

It is no coincidence that Francis Collins's tenure at the National Human Genome Research Institute marked one of the most extraordinary periods in modern science.

Full story

05/21/08 President Bush signs long-awaited Genetic Information Nondiscrimination Act


Signed into law today, GINA provides vital protection for Americans against the misuse of genetic test results by health insurers and employers.

Full story

05/15/08 Center to hold personal genomics seminar June 10

The seminar, "The Molecular Full Monty: Personal Genomes, Personal Health" will take place at the National Press Club at

Full story



Internet

# Mission

- The Center works to help policy leaders, decision makers, and the public better understand the rapidly evolving field of human genetics and its application to healthcare. . . . To inform genetic policy decisions, the Center surveys public attitudes about genetics issues, conducts analyses of the existing regulatory landscape, monitors the transition of genetic applications into clinical practice, and posits options and likely outcomes of key genetics policies.

# Goals of Regulation

- Protect the public
- Foster innovation
- Create uniform rules to prevent market inequalities (“level playing field”)

# Mechanisms of Regulation

- Many “tools” in the toolbox
- The right “tool” depends on the problem one is trying to fix or prevent, or the good one is trying to maintain or achieve



# Tools of Regulation

- Statute
- Regulation
- Incentives/Penalties (e.g., taxes, subsidies)
- Tort law
- Private mechanisms (e.g., professional societies)




# Goals of Genetic Testing Oversight

1. High quality laboratory testing
2. Clinically valid tests
3. Truthful, non-misleading claims about test benefits and limitations
4. Continued development of new tests
5. Appropriate and timely translation into clinical practice

Public confidence

# Challenges to Oversight of Genetic Tests

- Rapidly moving technology
  - tests for more than 1500 diseases



Data source: GeneTests database (2007) / [www.genetests.org](http://www.genetests.org)



# Challenges to Oversight of Genetic Tests

- Old laws, new situations
  - need for continued updating of regulations to respond to new technologies
  - the laws may not “fit” the new context neatly



# Challenges to Oversight of Genetic Tests

- Prospective v. reactive
- Many government actors potentially involved

# Federal Oversight

Department of Health  
& Human Services

Food & Drug  
Administration

Centers for Disease  
Control & Prevention

Centers for  
Medicare &  
Medicaid Services

Regulates  
drugs, devices,  
biological  
products,  
human tissue

Advice

Certification of  
clinical laboratories,  
personnel  
standards, QA/QC,  
proficiency testing

# CLIA

## Definition of a Clinical Laboratory:

*A laboratory that examines materials “derived from the human body” in order to provide “information for the diagnosis, prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings.”*

# Components of Laboratory Oversight

- Certification
- Inspection
- General requirements relating to QC, personnel, documentation, etc.
- More specific and tailored requirements for laboratories performing “high complexity” tests are set forth through the creation of “specialty areas”

# CLIA and Genetic Tests

- Law passed in 1988, regulations implemented in 1992
- Not specific to genetic tests
- Need to ensure that laboratory requirements appropriately include genetic testing laboratories
  - Proficiency testing
- Need to ensure that public has necessary information about laboratory quality

# FD&C Act

- Gives FDA authority to approve pharmaceuticals and medical devices before they are marketed

# FDA and Genetic Tests

- Regulatory status of genetic tests depends on how the laboratory develops and performs the test
  - Test kit/test system = regulation as medical device
  - Laboratory-developed = no FDA regulation
- Most genetic tests are laboratory developed
- Most genetic tests not required to demonstrate clinical validation



# IVDMIA Draft Guidance (July 2007)

- Defines new category of laboratory test -- “in vitro diagnostic multivariate index assays”
- Hallmarks of IVDMIAs
  - measure multiple analytes simultaneously (e.g., multiple gene or gene expression products)
  - use proprietary algorithm to calculate patient-specific result
  - provide result that cannot be independently interpreted by physician
- Require premarket clearance/premarket review by FDA
- Must demonstrate analytic and clinical performance of test

# Challenges to Oversight of Genetic Tests



# Meanwhile, on the Internet...



Fetal Gender



Inherited




Pharma



Complex Disorders



Paternity



Ancestry



Nutrition




Athletic perf.



Complex Conditions



Infidelity



Skin care



Recreational



Infertility



July 27, 2006:

## Senate Hearing, Special Committee on Aging, “At Home DNA Tests: Marketing Scam or Medical Breakthrough”



**GAO**  
Accountability-Integrity-Reliability  
**Highlights**

Highlights of [GAO-06-977T](#), testimony before the Special Committee on Aging, U.S. Senate

### Why GAO Did This Study

Scientists increasingly believe that most, if not all, diseases have a genetic component. Consequently, genetic testing is becoming an integral part of health care with great potential for future test development and use. Some genetic tests are sold directly to the consumer via the Internet or retail stores, and purport to use genetic information to deliver personalized

July 27, 2006

## NUTRIGENETIC TESTING

### Tests Purchased from Four Web Sites Mislead Consumers

### What GAO Found

The results from all the tests GAO purchased mislead consumers by making predictions that are medically unproven and so ambiguous that they do not provide meaningful information to consumers. Although there are numerous disclaimers indicating that the tests are not intended to diagnose disease, all 14 results predict that the fictitious consumers are at risk for developing a range of conditions, as shown in the figure below. However, although some types of diseases, such as cystic fibrosis, can be definitively diagnosed by looking at certain genes, the experts GAO spoke with said that the medical predictions in the tests results can not be medically proven at this time.

Medical Conditions Predicted for 14 Fictitious Consumers

“The results from all the tests GAO purchased mislead consumers by making predictions that are medically unproven and so ambiguous that they do not provide meaningful information to consumers.”



### Why GAO Did This Study

Scientists increasingly believe that most, if not all, diseases have a genetic component. Consequently, genetic testing is becoming an integral part of health care with great potential for future test development and use. Some genetic tests are sold directly to the consumer via the Internet or retail stores, and purport to use genetic information to deliver personalized nutrition and lifestyle guidance. These tests require consumers to self-collect a sample of genetic material, usually from a cheek swab, and then forward the sample to a laboratory for analysis. Companies that market this type of test claim to provide consumers with the information needed to tailor their diet and exercise programs to address their genetically determined health risks.

GAO was asked to investigate the “legitimacy” of these claims. This testimony reflects the findings of GAO’s investigation of a nonrepresentative selection of genetic tests. Specifically, GAO purchased tests from four Web sites and created “fictitious consumers” by submitting for analysis 12 DNA samples from a female and 2 samples from an unrelated male, and describing this DNA as coming from adults of various ages, weights, and lifestyle descriptions. GAO also consulted with experts in genetics and nutrition.

[www.gao.gov/cgi-bin/getrpt?GAO-06-977T](http://www.gao.gov/cgi-bin/getrpt?GAO-06-977T).

To view the full product, including the scope and methodology, click on the link above. For more information, contact Greg Kutz at 202-512-7455 or [kutzg@gao.gov](mailto:kutzg@gao.gov).

July 27, 2006


## NUTRIGENETIC TESTING

### Tests Purchased from Four Web Sites Mislead Consumers

#### What GAO Found

The results from all the tests GAO purchased mislead consumers by making predictions that are medically unproven and so ambiguous that they do not provide meaningful information to consumers. Although there are numerous disclaimers indicating that the tests are not intended to diagnose disease, all 14 results predict that the fictitious consumers are at risk for developing a range of conditions, as shown in the figure below. However, although some types of diseases, such as cystic fibrosis, can be definitively diagnosed by looking at certain genes, the experts GAO spoke with said that the medical predictions in the tests results can not be medically proven at this time.

#### Medical Conditions Predicted for 14 Fictitious Consumers



Source: GAO.

Even if the predictions could be medically proven, the way the results are presented renders them meaningless. For example, many people “may” be “at increased risk” for developing heart disease, so such an ambiguous statement could relate to any human that submitted DNA.

Results from the tests that GAO purchased from Web sites 1 and 4 further mislead the consumer by recommending costly dietary supplements. The results from the tests from Web site 1 suggested “personalized” supplements costing approximately \$1,200 per year. However, after examining the list of ingredients, GAO found that they were substantially the same as typical vitamins and antioxidants that can be found in any grocery store for about \$35 per year. Results from the tests from Web site 4 suggested expensive products that claimed to repair damaged DNA. However, the experts GAO spoke with stated that there is no “pill” currently available that has been proven to do so. The experts also told us that, in some circumstances, taking supplements such as those recommended may be harmful.

In addition, results from the tests that GAO purchased from Web sites 1, 2, and 3 do not provide recommendations based on a unique genetic profile as promised, but instead provide a number of common sense health recommendations. If the recommendations were truly based on genetic analysis, then the 9 fictitious consumers that GAO created for these sites using the female DNA should have received the same recommendations because their DNA came from the same source. Instead, they received a variety of different recommendations, depending on their fictitious lifestyles. For example, when GAO created lifestyle descriptions stating that the consumers smoked, they received recommendations to stop smoking. In contrast, if GAO said the consumers never smoked, they received recommendations to continue to avoid smoking.

United States Government Accountability Office

# Federal Trade Commission releases consumer advisory, “At Home Genetic Tests: A Healthy Dose of Skepticism May Be the best Prescription” (July 2006)

“...some of these tests lack scientific validity, and others provide medical results that are meaningful only in the context of a full medical evaluation.”

## FTC FACTS for Consumers

### At-Home Genetic Tests:


### A Healthy Dose of Skepticism May Be the Best Prescription




**C**ould a simple medical test tell you if you are likely to get a particular disease? Could it evaluate your health risks and even suggest a specific treatment? Could you take this test in the privacy of your home, without a doctor's prescription or guidance?

Some companies say genetic testing can do all this and more. They claim that at-home genetic testing can screen for diseases and provide a basis for choosing a particular diet, dietary supplement, lifestyle change, or medication. They sell their tests in supermarkets and drugstores, and they advertise their services in print, on television, and online.

The Federal Trade Commission (FTC) wants you to know the facts about the direct-to-consumers marketing of genetic tests. According to the Food and Drug Administration (FDA), which regulates the manufacturers of genetic tests; and the Centers for Disease Control and Prevention (CDC), which promotes health and quality of life, **some of these tests lack scientific validity, and others provide medical results that are meaningful only in the context of a full medical evaluation.** The FDA and CDC say that because of the complexities involved in both the testing and the interpretation of the results, genetic tests should be performed in a specialized laboratory, and the results should be interpreted by a doctor or trained counselor who understands the value of genetic testing for a particular situation.

# State DTC Testing Statutes and Regulations



-  DTC Permitted
-  Limited
-  DTC Not Permitted

Source: Genetics and Public Policy Center, <http://www.dnapolicy.org/resources/DTCStateLawChart.pdf>



# ACMG Statement on DTC


April 7, 2008

- A knowledgeable professional should be involved in the process of ordering and interpreting a genetic test.
- The consumer should be fully informed regarding what the test can and cannot say about his or her health.
- The scientific evidence on which a test is based should be clearly stated.
- The clinical laboratory must be accredited by CLIA, the state and/or other applicable accrediting agencies.
- Privacy concerns must be addressed.

# ASHG Statement on DTC

1. DTC companies should provide accurate information
2. Government actors should provide adequate oversight
3. Not all tests the same – DTC may be appropriate for some but not others

# Pharmacogenetics: The Promise



↑ Safety

↑ Effectiveness


↓ Cost

= Better patient care

# Pharmacogenetics: The reality

A few examples:

- Her2/neu and Herceptin
  - Only “co-developed” drug and test
- UGT1A1 and Irinotecan
- EGFR and Iressa
- HLA B and Abacavir
- CYP450 and Warfarin?????



# Prerequisites for Pgx Success

1. Robust and responsive research enterprise
2. Regulatory system that encourages development of safe and effective tests
3. Mechanism for evidence development and translation to clinical practice
4. Fair reimbursement
5. Safeguards for genetic information

Public confidence

- Policy development is still evolving
- Legislation pending
- Recent recommendations by the SACGHS provide direction for future government activities



# The Pew Charitable Trusts

